Status and phase
Conditions
Treatments
About
A Concentration-QT Interval Correction (C-QTc) study of MY008211A Tablets in Healthy Subjects
Full description
This is a single-center, randomized, double-blind, single oral dose, two groups, placebo-controlled study with 2 dose sequences preset
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
16 participants in 4 patient groups, including a placebo group
Loading...
Central trial contact
Yuhui Hu, master
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal